Tyra Biosciences, Inc. (Nasdaq: TYRA), a California-based clinical-stage biotechnology company involved in developing medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced on Tuesday that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA.
The presentation will highlight preclinical data on TYRA-300, Tyra's lead investigational FGFR3-selective inhibitor. The poster, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be presented by Jacqueline H. Starrett, Ph.D., on July 13, 2025, from 12:00 PM to 1:30 PM during Session P70 on rare bone and genetic disorders.
TYRA-300, developed through Tyra's proprietary SNÅP platform, is currently in clinical development for both oncology and genetic skeletal disorders. It is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasia that the company says has demonstrated interim clinical proof-of-concept results in metastatic urothelial cancer (mUC).
Planned Phase 2 trials for TYRA-300 include SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval